AGMB FY 2024 Earnings Report — AgomAb Therapeutics N.V. American Depositary Shares Revenue & Financial Results | Market Cap Arena

AgomAb Therapeutics N.V. American Depositary SharesAGMB

FY 2024 Earnings

Reported December 31, 2024

Quarter Comparison

Revenue

Operating Income

EPS (Diluted)

Metric	FY 2024	Prior Q	FY 2023	QoQ Change	YoY Change
Revenue	$0	—	$0	—	—
Op. Income	-$56M	—	-$36M	—	-54.0%
EPS (Diluted)	$-1.47	—	$-0.36	—	-306.5%

Income Statement

Item	Amount
REVENUE	$0
Cost of Revenue	$0
GROSS PROFIT	$0
R&D Expenses	$46M
Selling & Marketing	$0
General & Administrative	$11M
SG&A Expenses	$11M
Other Expenses	-$1M
Operating Expenses	$56M
Cost & Expenses	$56M
OPERATING INCOME	-$56M
Interest Income	$1M
Interest Expense	$78.3K
Other Income/Expenses	$2M
INCOME BEFORE TAX	-$54M
Income Tax Expense	$4.7K
Net Income from Continuing Ops	-$54M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	-$54M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	-$54M
D&A	$363.6K
EBIT	-$54M
EBITDA	-$54M
EPS	-$1
EPS Diluted	-$1